Abstract
Abstract
Purpose
To demonstrate the feasibility of continuous infusion of meropenem–vaborbactam to optimize the treatment of carbapenem-resistant Enterobacterales.
Methods
Report of a case of a Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae bloodstream infection comfirmed by whole genome sequencing and therapeutic drug monitoring (TDM) of meropenem.
Results
A patient with augmented renal clearance (ARC) went into septic shock caused by an ST11 KPC-3-producing K. pneumoniae bloodstream infection that was successfully treated with a continuous infusion of meropenem–vaborbactam at a dosage of 1 g/1 g q4h as a 4-h infusion. TDM confirmed sustained concentrations of meropenem ranging from 8 to 16 mg/L throughout the dosing interval.
Conclusion
Continuous infusion of meropenem–vaborbactam was feasible. It could be appropriate for optimizing the management of critically ill patients with ARC, as it resulted in antibiotic concentrations above the minimum inhibitory concentration for susceptible carbapenem-resistant Enterobacterales (up to 8 mg/L) throughout the dosing interval.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference15 articles.
1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet Lond Engl. 2022;399:629–55.
2. Wenzler E, Scoble PJ. An appraisal of the pharmacokinetic and pharmacodynamic properties of meropenem–vaborbactam. Infect Dis Ther. 2020;9:769.
3. Summary of product characteristics: Vaborem [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/vaborem-epar-product-information_en.pdf. Accessed 23 Mar 2023
4. Silva CM, Baptista JP, Santos I, Martins P. Recommended antibiotic dosage regimens in critically ill patients with augmented renal clearance: a systematic review. Int J Antimicrob Agents. 2022;59:106569.
5. Rebold N, Lagnf AM, Alosaimy S, Holger DJ, Witucki P, Mannino A, et al. Risk factors for carbapenem-resistant enterobacterales clinical treatment failure. Goldberg JB, editor. Microbiol Spectr. 2023;11:e02647-22.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献